We have previously postulated that the binding of the human immunodeficiency virus type 1 (HIV-1) to cell surface CD4 induces signal transduction pathways that down-modulate production of progeny virions in acutely infected T cells (M. Tremblay, S. Meloche, S. Gratton, M. A. Wainberg, and R.-P. Sékaly, EMBO J. 13:774-783, 1994). To evaluate the possibility that CD4 cross-linking might indeed affect viral gene expression, we have introduced a molecular construct made of the luciferase reporter gene placed under the control of the regulatory elements of HIV-1 in several CD4-positive T-cell lines. We found that cross-linking of CD4 with defective HIV-1 particles and heat-inactivated viruses inhibits long terminal repeat-dependent luciferase expression. Experiments revealed that the gp120-CD4 interaction was necessary to repress HIV-1 long terminal repeat-dependent luciferase activity. The cytoplasmic domain of CD4 was also found to be required for this effect to occur. The virus-mediated signal transduction was shown to be mediated via p56 lck -dependent and -independent pathways. These results indicate that the earliest event in the HIV-1 replicative cycle, namely, the binding of the virus to its cellular receptor, can lead to signal transduction culminating in down-modulation of viral gene expression. Thus we propose that defective viruses could regulate the pathogenesis of HIV disease as they constitute the vast majority of circulating HIV-1 particles. a Percentage of CD4 ϩ cells as measured by flow cytometry with the Leu-3A anti-CD4 antibody (Becton Dickinson). b MFI, linear-scale mean fluorescence intensity of CD4 on studied cells.
The CD4 antigen is a glycoprotein of approximately 55,000 in molecular weight expressed primarily on the surface of a functionally distinct population of human T cells and, to a lesser extent, on cells of the monocyte/macrophage lineage (57, 65, 73) . It has been proposed that CD4 functions as an adhesion structure that interacts with nonpolymorphic determinants located on the major histocompatibility complex (MHC) class II molecules, thereby stabilizing and facilitating the MHC class II-T-cell receptor (TCR) complex interaction (18, 23, 51, 72) . Other studies have also indicated that CD4 can actively participate in transmembrane signal transduction. The initial evidence that the cell surface CD4 glycoprotein is playing an active role as a signal transduction molecule came from the demonstration that, without appropriate MHC class II recognition, anti-CD4 antibodies abrogated lectin-induced T-cell mitogenesis (3, 66, 74, 80) . Results from these studies suggest that the CD4 molecule negatively affects T cells when this structure is ligated independent of the TCR. In contrast, the binding of the coreceptor molecule CD4 to the same MHC class II molecule as the TCR results in an optimal T-cell activation (19, 20, 36, 42, 44, 45) . Greater activation of the T lymphocytes is observed when the TCR and the coreceptor CD4 bind to the same ligand, suggesting that CD4 actively participates in transmembrane signal transduction through the TCR. This has led to the concept of receptor cooperativity in T-cell signaling and activation (35) .
Beside its role in antigen-specific T-cell activation, CD4 is also established as the major cellular receptor for the human immunodeficiency virus (HIV) (16, 39) . Viral tropism is mediated by the high-affinity interaction between CD4 and the major viral envelope glycoprotein gp120 (43, 52) . There have been conflicting reports on the ability of HIV and/or gp120 to transduce signaling through the CD4-p56 lck complex. Ligation of CD4 by gp120 has been demonstrated to generate stimulation or modification of protein kinase C activity, an increase in the intracellular calcium concentration, activation of protein tyrosine kinases, arachidonic acid metabolism, and interleukin 1 (IL-1) release (15, 21, 27, 41, 59, 79) . Furthermore, binding of gp120 or HIV to CD4 has also been shown to abrogate anti-TCR-induced calcium mobilization, IL-2 production, proliferation, and antigen-specific T-cell responses (13, 17, 27, 48, 50, 55, 61) . However, others have failed to observe these events (33, 38, 60) . Such contradictory results may be associated with variations in technical approaches.
Recently, we and others have demonstrated that cross-linking of cell surface CD4 can result in inhibition of HIV type 1 (HIV-1) replication at a postbinding step (4, 10, 14, 29, 31, 56, 76) . Cross-linking of CD4 was achieved in these experiments with anti-CD4 antibodies (4, 10, 14, 31, 56) , recombinant HIV-1-like particles carrying viral envelope proteins (29) , and, more importantly, whole HIV-1 particles (76) . The demonstration that the binding of viruses to already infected cells results in a decrease of virus production is of great interest because it implies that HIV-1 could regulate its own replication.
In this study, we used a molecular construct made of a reporter gene placed under the control of the regulatory elements of HIV-1. Whole heat-inactivated and defective HIV-1 particles were used to cross-link surface CD4. Cell lines car-rying wild-type and mutated forms of CD4, as well as wild-type p56 lck , were generated to investigate in depth the signaling pathway. Our results demonstrate that the binding of HIV-1 to the CD4 glycoprotein can markedly reduce long terminal repeat (LTR)-driven reporter gene activity. Furthermore, we present evidence that the signal transduction pathway requires the cytoplasmic domain of CD4 and is partly mediated through the CD4-associated protein tyrosine kinase p56 lck .
(This work was performed by P. Bérubé in partial fulfillment of the requirements for his graduate studies in the Department of Microbiology and Immunology, Faculty of Medicine, Laval University.)
MATERIALS AND METHODS
Cells and culture conditions. 1G5 is a derivative of Jurkat E6-1 that contains a stably integrated HIV-1 SF-2 LTR-luciferase construct (1), C8166-45 is an IL-2-independent human T-cell leukemia virus type 1-transformed T-cell line that does not express p56 lck (40) , Jurkat-tat is a Jurkat E6-1 derivative stably expressing the HIV-1 Tat protein (11), Sup-T1 cells express high levels of surface CD4 (70), WE17/10 is a human IL-2-dependent T-lymphoblastoid cell line (81) , and A2.01 is a human leukemic CD4-negative cell line (22) . These cell lines were provided by the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases (Rockville, Md.). Cell lines were maintained in complete culture medium made of RPMI 1640 supplemented with 10% fetal calf serum, glutamine (2 mM), penicillin G (100 U/ml), and streptomycin (100 g/ml).
Flow cytometry analysis. Levels of surface CD4 molecule were detected by direct immunofluorescence with a cytofluorimeter. Briefly, 10 5 cells were first incubated with an experimentally determined saturating concentration of a fluorescein-conjugated anti-human CD4 antibody (Leu-3a; Becton Dickinson) for 30 min on ice. After two washes with phosphate-buffered saline, samples were fixed with 1% (vol/vol) of paraformaldehyde and analyzed by a cytofluorimeter. Controls consisted of a commercial isotype-matched murine antibody (Sigma, St. Louis, Mo.).
Viruses. Stocks of infectious HIV-1 IIIB and HIV-1 IIIRF were prepared from acutely infected H9 cells. The IIIB and IIIRF strains of HIV-1 were kindly provided by R. C. Gallo through the AIDS Research and Reference Reagent Program as cell-free supernatant from infected H9 cells. The clinical isolate HIV-1 334 was grown on phytohemagglutinin-activated peripheral blood mononuclear cells isolated from healthy donors and has been described previously (77) . Defective HIV-1 IIIB particles were also used in our experiments and originate from cellular clone UHC-8 (9) . Virus particles harvested from this cell line are devoid of both reverse transcriptase and integrase proteins (8) . Virus stocks were quantitated by measuring the amount of the major viral core p24 protein by a commercial enzymatic assay (Organon Teknika, Durham, N.C.).
Generation of cells stably transfected with cDNA encoding wild-type, truncated, and mutated forms of CD4, as well as wild-type p56 lck . Truncated (t-CD4) and mutated (C4202A) CD4 constructs were generated as previously described (76) . Briefly, a stop codon was introduced into the cDNA coding for human CD4, leading to deletion of 32 of 38 amino acids located in the cytoplasmic domain of CD4. The mutated CD4 was achieved by substituting cysteines at positions 420 and 422 with alanines by a PCR overlap extension procedure. The full-length human p56 lck cDNA originates from the pHK-28 plasmid (kindly provided by R. M. Perlmutter, Seattle, Wash.). The various molecular constructs were subcloned in the eukaryotic expression retroviral vector pMNC, which contains the neo-mycin (G418) resistance gene and a cytomegalovirus promoter for eukaryotic gene expression (69) . The amphotropic helper packaging cell line DAMP (63) was transfected with the different pMNC constructs by the calcium phosphate transfection technique. The resulting recombinant amphotropic retrovirus particles containing the cDNA of interest driven by the cytomegalovirus promoter region and the neo gene driven by the LTR of the Moloney murine leukemia virus were used to infect cells of interest. Stable cellular transfectants were cultured in complete culture medium supplemented with appropriate concentrations of the selective agent G418 (Gibco-BRL, Gaithersburg, Md.).
Transfection, cell treatments, and luciferase assay. Cells (10 ϫ 10 6 ) were washed once in TS (25 mM Tris-HCl [pH 7.4], 5 mM KCl, 0.6 mM Na 2 HPO 4 , 0.5 mM MgCl 2 , and 0.7 mM CaCl 2 ) and resuspended in 1 ml of TS containing the desired plasmid(s) and 500 g of DEAE-dextran per ml (final concentration). Plasmids pLTRX-LUC and pCMVtat were provided by O. Schwartz (Unité d'Oncologie Virale, Institut Pasteur, Paris, France). The pLTRX-LUC plasmid contains a 722-bp XhoI (Ϫ644)-HindIII (ϩ78) fragment from HIV-1 LAI placed in front of the luciferase reporter gene, and the pCMVtat vector contains the immediate early enhancer/promoter region of the human cytomegalovirus placed upstream of the viral tat gene (67) . The pCMV-LUC vector has been provided by A. Darveau (Laval University, Ste-Foy, Quebec, Canada). The cell-TS-plasmid(s)-DEAE-dextran mix was incubated for 15 min at room temperature. Thereafter, cells were diluted at a concentration of 10 6 /ml by using complete culture medium supplemented with 100 M chloroquine (Sigma). After 45 min of incubation at 37ЊC, cells were centrifuged, washed once, and seeded in 96-well flat-bottomed plates at a density of 5 ϫ 10 4 cells per well (100 l) in the presence of 20 ng of phorbol myristate acetate (PMA) per ml (Sigma). Cells were inoculated with heat-inactivated or defective HIV-1 particles. Heat-inactivated HIV-1 particles (HIV-1 IIIB , HIV-1 IIIRF , and HIV-1 334 ) originated from frozen virus stocks that were thawed and incubated at 56ЊC for 30 min before their use, while fresh cell-free culture supernatant from UHC-8 cells filtered through a 0.45-m-pore-size membrane was used as a source of defective HIV-1 particles. The amount of defective HIV-1 particles used to cross-link CD4 varied from one experiment to another because levels of p24 in fresh unfrozen clarified UHC-8 cell supernatant were unknown when the assays were initiated. In some experiments, recombinant soluble CD4 was also added to the culture medium. After 24 h of incubation at 37ЊC, cells were centrifuged and resuspended in cell culture lysis reagent (Promega, Madison, Wis.). Cells were next incubated at room temperature for 30 min, and the lysates were clarified from insoluble material by centrifugation. Samples were then mixed with the luciferase assay buffer (Promega) and counted for 50 s in a standard liquid scintillation counter (Beckman Instruments, Fullerton, Calif.) equipped with single-photon monitor software. This technique has been previously shown to be very sensitive and appropriate to detect HIV-1 LTR-driven luciferase activity in mammalian cell lysates (67) .
RESULTS

Cross-linking of CD4 by different isolates of HIV-1 leads to a decrease in HIV-1 LTR-dependent gene activity.
To investigate the modulatory effects of virus-mediated CD4 cross-linking on the HIV-1 regulatory elements, a molecular construct harboring the LTR region positioned upstream of the luciferase reporter gene (pLTRX-LUC) was introduced into several T-lymphoid cell lines by transient transfection. Characteristics of these cell lines are presented in Table 1 . Surface CD4 expression determined by fluorescence-activated cell sorter analysis with the anti-CD4 Leu-3A antibody is also indicated for each cell line. We first sought to determine whether the binding of HIV-1 to cell surface CD4 could regulate HIV-1 LTR activity. Since we judged that it was critical for our assays to abolish subsequent postbinding steps in the virus replicative cycle, experiments were carried out with defective HIV-1 IIIB harvested from the cellular clone UHC-8. Viral particles produced by this cell line have been demonstrated to be devoid of both reverse transcriptase and integrase proteins (8) . Furthermore, two laboratory isolates (HIV-1 IIIRF and HIV-1 IIIB ) and one clinical isolate (HIV-1 334 ) of HIV-1 were also tested. In this set of experiments, frozen virus stocks were thawed and heat inactivated before incubation with transfected cells, as this physical treatment has been shown to abolish virus infectivity without disrupting binding (53) . LTR-driven luciferase activity was monitored after a 24-h incubation period with viruses, based on preliminary experiments which demonstrated that optimal luciferase activity was obtained at this time point (data not shown). As shown in Fig. 1A , all HIV-1 strains tested in transfected Jurkat-tat cells inhibited LTR-driven expression. Interestingly, the degree of inhibition was stronger with defective particles (74%) than with other heat-inactivated strains of HIV-1 (ranging from 17 to 39%) despite the use of half as many viruses, as estimated by their p24 content. The inhibitory effect on luciferase gene expression induced by defective HIV-1 IIIB particles was next evaluated in other CD4 ϩ T-lymphoid cell lines and gave levels of inhibition ranging between 31 and 71% ( Fig. 1B) , thereby suggesting that this phenomenon is not cell type specific. The presence of surface CD4 was found to be important as the lowest inhibitory effect was seen in 1G5 (31%), a cell line expressing lower levels of CD4 on a lower percentage of cells (Table 1 ). More importantly, treatment of the CD4-negative A2.01 T-cell line with defective HIV-1 IIIB did not result in a decrease of LTR-driven luciferase gene expression, thereby supporting even further the critical role played by CD4 in this phenomenon. Data with the A2.01 cell line also suggest that the virus-mediated diminution of HIV-1 LTR-driven luciferase activity was not mediated by cellular soluble factor(s) that may affect cell proliferation and/or viability. Moreover, our results indicate that the strain origin of the LTR is not a determinant in the inhibitory process, as the LTR from the pLTRX-LUC construct is derived from HIV-1 LAI , while the regulatory elements of the integrated LTRdependent luciferase vector in 1G5 cells originate from HIV-1 SF-2 .
The necessity of the presence of HIV-1 for this effect to occur was next investigated by using Sup-T1 since maximal inhibition of LTR-dependent reporter gene activity was seen in these cells. A dose-dependent decrease of HIV-1 LTR-modulated gene expression was seen when using increasing concentrations of defective HIV-1 IIIB ( Fig. 2A) . Inhibition of luciferase activity was found to be specific for the regulatory elements of HIV-1, as incubation of transfected Jurkat-tat and Sup-T1 cells with defective HIV-1 IIIB particles had no inhibitory effect on luciferase activity when this reporter gene was placed under the control of the immediate early enhancer/ promoter region of the human cytomegalovirus (Fig. 2B) . Furthermore, the observation that shutoff of transcription does not extend to all gene promoters is another indication that the virus-induced repression of HIV-1 LTR-driven luciferase activity is independent of soluble cellular factors.
Repression of LTR-dependent gene expression is independent of Tat and of PMA-induced translocation of NF-B. To delineate the mechanism of virally induced repression of LTRmediated gene activity, virus particles were incubated with transfected Sup-T1 cells in the absence or presence of the transactivating viral Tat protein. As depicted in Table 2 , similar repression of LTR-dependent luciferase activity was seen in the presence of the viral Tat protein (69%) or in a Tat-free system (71%). As expected, the addition of the vector encoding Tat was associated with an increase in reporter gene activity even though three times less LTRX-LUC was used in this transfection.
Next, to investigate the putative involvement of the transcription factor NF-B, experiments were performed in the presence or absence of the phorbol ester PMA, a known inducer of NF-B nuclear translocation (58) . We detected comparable levels of inhibition when Jurkat-tat cells were incubated with defective HIV-1 IIIB in the presence or absence of PMA (Table 3) . Jurkat-tat cells were transfected by DEAE-dextran with pLTRX-LUC at 15 g/10 ϫ 10 6 cells and were next incubated for 24 h at 37ЊC with PMA and HIV-1 (900 pg of p24 from heat-inactivated frozen stocks of HIV-1 IIIB , HIV-1 IIIRF , and HIV-1 334 ; 450 pg of p24 from defective HIV-1 IIIB harvested from fresh UHC-8 cell supernatant). (B) 1G5 cells were transfected by DEAE-dextran with 15 g of pCMVtat; Sup-T1, WE17/10, and A2.01 cells were cotransfected with 5 g of pLTRX-LUC and 10 g of pCMVtat. Cells were next incubated for 24 h at 37ЊC with PMA and 400 pg of p24 from defective HIV-1 IIIB harvested from fresh UHC-8 cell supernatant. Luciferase activity was monitored as described in Materials and Methods. Results shown are the mean values (in 10 3 cpm) of triplicate samples Ϯ standard deviations. The percentage of inhibition of luciferase activity was calculated with the formula % inhibition ϭ 100 ϫ 1 Ϫ (mean value for PMA-treated cells incubated with HIV-1/mean value for PMA-treated cells).
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Interaction between gp120 and CD4 is required to achieve a virally mediated repression of HIV-1 LTR-driven gene activity.
We next evaluated the role played by gp120-CD4 interactions in the present phenomenon by exploiting the reported weak association between the external envelope gp120 and the transmembrane gp41 proteins, which frequently results in shedding of surface gp120 spikes from the virion (25) . As shown in Fig.  3A , inhibition of LTR-driven luciferase activity was markedly decreased when Sup-T1 cells were incubated with defective HIV-1 IIIB particles denuded of their external envelope protein gp120 by freeze-thaw cycle(s). These results may explain the diminished ability demonstrated by HIV-1 IIIRF , HIV-1 IIIB , and HIV-1 334 to repress LTR-driven reporter gene expression compared with defective particles originating from fresh UHC-8 culture supernatant (Fig. 1A) . Treatment with 20 g of soluble CD4 per ml was sufficient to almost abrogate the HIV-1-mediated decrease of LTR-driven luciferase activity (Fig.  3B) , thereby reinforcing the notion that the binding of HIV-1 to its primary cellular receptor is an event that is required to generate the virus-mediated decrease in HIV-1 LTR-driven reporter gene expression.
The signaling event leading to virus-mediated repression of HIV-1 LTR-driven gene activity requires the cytoplasmic domain of CD4 and is transduced via p56 lck -dependent and -independent pathways. We next investigated the importance of the cytoplasmic domain of CD4 by introducing three different CD4 constructs within the A2.01 CD4-negative cell line. No decrease in HIV-1 LTR-driven reporter gene activity was seen either for the parental CD4-negative cell line or for cells expressing a CD4 molecule truncated at position 402 (A2.01/t-CD4), which can no longer interact with endogenous p56 lck . However, introduction of a full-length CD4 glycoprotein (A2.01/wt-CD4) gave rise to a marked diminution of luciferase activity following CD4 cross-linking with defective HIV-1 IIIB particles (inhibition of 52%) (Fig. 4A ). On the other hand, the expression of a CD4 construct with cysteines at positions 420 and 422 substituted for alanines (A2.01/C4202A), residues that have been reported to be responsible for the physical association of CD4 with p56 lck (68, 78) , restored only partially the virus-mediated inhibition of HIV-1 LTR-driven reporter gene expression (inhibition of 21%). On the basis of these results suggesting that the signaling pathway is mediated at least in part via p56 lck , it was of interest to further investigate the role played by this CD4-associated tyrosyl kinase in this process. To more directly measure the importance of p56 lck , we stably transfected the p56 lck -negative C8166-45 cell line with a cDNA coding for the wild-type p56 lck protein. Incubation of the parental p56 lck -negative cell line with defective HIV-1 IIIB resulted in a minimal diminution of LTR-driven luciferase activity (9%), while the expression of p56 lck was associated with a marked enhancement of the observed inhibition (70%) (Fig.  4B ). Altogether, these results indicate that the cytoplasmic domain of CD4 is necessary for the HIV-1-induced repression of LTR-mediated gene activity and suggest that the CD4associated tyrosyl kinase p56 lck is also one of the elements participating in the signaling pathway.
DISCUSSION
The aim of this study was to determine the effect of virusmediated CD4 cross-linking on viral gene expression in an effort to elucidate the molecular basis for our previous observations suggesting that the binding of HIV-1 particles to CD4 down-modulates virus expression in infected cells acutely infected with HIV-1 (76) . In the present study, we used a mo- a Sup-T1 cells were transfected with 15 g of pLTRX-LUC alone or cotransfected with 5 g of pLTRX-LUC and 10 g of pCMVtat prior to incubation for 24 h at 37ЊC with PMA in the presence or absence of defective HIV-1 IIIB .
b Results shown are the mean 10 3 cpm Ϯ standard deviations of triplicate samples. lecular construct consisting of a vector containing the regulatory elements of HIV-1 (LTR region) placed in front of the reporter luciferase gene. Others have also reported that crosslinking of CD4 glycoproteins can inhibit HIV-1 gene expression. Indeed, it was shown that an anti-CD4 antibody (IOT4A/ 13B8-2), specific for the CDR3-like region of CD4, was able to inhibit HIV-1 replication at a late step in the virus replicative cycle by blocking provirus transcription (4, 5, 7) . In in vitro tissue culture experiments, with peripheral blood mononuclear cells isolated from HIV-1-infected individuals stimulated with anti-CD3 antibodies, virus production from such latently in-fected cells was markedly diminished by treatment with recombinant particles carrying HIV-1 envelope glycoproteins (29) . Interestingly, inhibition was not detected after treatment with recombinant HIV-1 particles expressing Gag proteins, suggesting that CD4 binding was required to achieve the observed inhibitory effect. 
FIG. 4. Inhibition of LTR-driven gene expression by HIV-1 is dependent on
the cytoplasmic domain of CD4 and partly on p56 lck . The parental A2.01 cell line (CD4 negative) and stable A2.01 transfectants expressing either the full-length version (A2.01/wt-CD4), the truncated version (A2.01/t-CD4), or a mutated form of CD4 (A2.01/C4202A) were cotransfected with 5 g of pLTRX-LUC and 10 g of pCMVtat. These cells were next incubated for 24 h at 37ЊC with PMA and defective HIV-1 IIIB contained in fresh UHC-8 cell supernatant (500 pg of p24). (B) The parental p56 lck -negative C8166-45 cell line and C8166-45 cells stably transfected with cDNA encoding wild-type p56 lck were cotransfected with 5 g of pLTRX-LUC and 10 g of pCMVtat. These cells were next incubated for 24 h with PMA and defective HIV-1 IIIB contained in fresh supernatant from UHC-8 (450 pg of p24). Data represent the means (in 10 3 cpm) of triplicate samples Ϯ standard deviations. We first investigated whether the binding of the virus to its cell surface receptor could induce repression of HIV-1 LTRdriven luciferase gene expression. We found that a decrease of LTR-dependent reporter gene activity was detected when transfected cells were incubated with different strains of HIV-1. A more pronounced inhibition of LTR-driven luciferase activity was seen with defective HIV-1 particles. We have presented evidence indicating that this seems associated with the fact that fresh supernatant was the source of defective particles, while heat-inactivated virus stocks were submitted to a freeze-thaw cycle before their use. The demonstration that freeze-thaw cycles abrogate the ability of HIV-1 to inhibit LTR-mediated reporter gene activity supports this notion. Furthermore, the inhibition process was diminished in a dosedependent fashion by treatment with soluble CD4 and was not seen in CD4-negative cells, indicating that the binding of HIV-1 particles to the cell surface CD4 glycoprotein is essential for the repression to occur. The virus-mediated decrease of HIV-1 LTR-driven luciferase activity is not a restricted phenomenon, as it was seen in six different CD4 ϩ T-lymphoid cell lines. The specificity for the regulatory elements of HIV-1 was demonstrated by the inability to achieve a similar inhibitory effect when cDNA coding for luciferase was placed under the control of the enhancer/promoter sequences of the cytomegalovirus.
The cross-linking of CD4 with antibodies has been shown to lead to a rapid and strong autophosphorylation of p56 lck and to an increase of its kinase activity on exogenous substrates (49) . We believe that binding of HIV particles to CD4-expressing cells will also lead to multimerization of its receptor. Indeed, it is logical to assume that HIV, which has a mean diameter of 100 nm and possesses an average of 216 to 288 gp120 molecules per virion (26) , will induce CD4 cross-linking at the contact site. It is thus likely that the observed inhibitory effect is dependent on multimerization of CD4 molecules and might thus be dependent on an interaction between the cytoplasmic region of CD4 and the protein tyrosine kinase p56 lck . The present transfection assays do indeed indicate that the CD4-p56 lck complex plays a critical role in virus-mediated repression of HIV-1 LTR-dependent reporter gene activity. However, our results revealed that, although weaker, another signaling pathway that is p56 lck independent is also participating in the virusmediated repression of LTR-driven gene activity. This is based on experiments showing partial inhibition of LTR-mediated luciferase activity in cells expressing CD4 with substitutions of cysteines 420 and 422 for alanines and in a cell line that lacks endogenous p56 lck . Further studies are needed to identify cellular signaling intermediates that couple HIV-1-mediated CD4 cross-linking with a decrease of LTR-driven gene expression.
The observed repression of HIV-1 LTR-dependent gene activity generated by the virus binding event is most likely attributable to cellular protein(s) interacting with DNA or RNA located within the regulatory elements of HIV-1. Numerous studies have shown that the regulatory elements of HIV-1 respond to several cellular transcription factors (reviewed in reference 24). The most widely studied binding domain of LTR is the NF-B element, which acts as an enhancer element in HIV-1 regulation (58) . Most of our assays were performed in the presence of the phorbol ester PMA, which has been reported to lead to the dissociation of the IB-NF-B protein complex and to the translocation of NF-B to the nucleus (46) . Moreover, treatment with PMA alone has been reported to efficiently activate the regulatory elements of HIV-1, which are composed of two NF-B binding sites (75) . Experiments carried out in the absence of PMA gave comparable levels of inhibition of LTR-dependent reporter gene expression in transfected cells incubated with HIV-1 IIIB . Therefore, it is likely that the PMA-induced increase in the amount of NF-B binding to HIV-1 LTR is not modulated by cross-linking of CD4 with viral particles. However, our studies cannot permit us to clearly demonstrate that the inhibition is totally NF-B independent. Indeed, basal levels of NF-B could similarly be affected by the binding of HIV-1 to its cellular receptor. This is supported by a recent study by Jabado et al. showing that CD4 cross-linking mediated either with different anti-CD4 antibodies or with purified gp120 prior to T-cell stimulation caused a reduction in NF-B binding to the regulatory elements of IL-2 (34) . Experiments performed with an HIV-1 LTR mutant with deletions in the NF-B binding sites would permit more direct measurement of the role played by NF-B in the inhibition process. Transcription of all viral messages is also markedly upregulated by the viral activating protein Tat (2, 71) . We have determined that the observed inhibition is Tat independent, as a similar HIV-1-mediated repression of LTR-driven luciferase activity was detected in transfected CD4 ϩ T cells despite the absence of this transactivating viral protein. This indicates that our mode of inhibition of the HIV-1 LTR is different from the one recently described in some studies showing a Tat-dependent mode of inhibition of LTR activity via the binding of antibodies to the CDR3-like region of the CD4 molecule (4, 5, 7).
Benkirane et al. have recently published that cross-linking of CD4 with heat-inactivated HIV-1 LAI induced activation of LTR-driven chloramphenicol acetyltransferase expression via an increased nuclear translocation of NF-B, suggesting that the binding of HIV-1 particles to CD4-expressing cells results in signal transduction that will positively modulate virus replication (6) . These observations are not in agreement with the present data and with previous findings from the same group and others which demonstrated that antibody-mediated crosslinking of CD4 can repress replication of HIV-1 at a postbinding step (4, 10, 14, 31, 56) . Additional studies are required to elucidate such a discrepancy. However, the fact that we have detected a decrease in LTR-directed reporter gene activity mediated by cross-linking of CD4 with three different HIV-1 isolates in six different T-cell lines is a strong indication that our observation is not fortuitous and is a broad phenomenon. Furthermore, since HIV-1 is known to be modulated at the transcriptional level after signaling through the TCR (75), it is logical that TCR-independent CD4 cross-linking, which has been reported to generate suboptimal T-cell stimulation (3, 66, 74, 80) , might negatively affect LTR-dependent gene expression.
Several lines of evidence clearly suggest that the integral membrane CD4 protein is an active component of the signaling cascade operating in T cells. Thus, ligation of CD4 by the external envelope gp120 glycoprotein can induce pleiotropic effects such as down-modulation of cell surface CD4, induction of p56 lck activation, dissociation of p56 lck from CD4, IL-6 production, and inhibition of anti-TCR-CD3-induced activation (12, 32, 37, 62) . We now demonstrate that cross-linking of cell surface CD4 glycoprotein with HIV-1 particles can also lead to repression of HIV-1 LTR-driven gene expression.
Our data suggest for the first time that HIV-1 can downmodulate its own replication by mediating a cascade of biochemical events leading to the repression of HIV-1 LTR-dependent gene expression through its primary cellular receptor. This is consistent with the in vivo situation in which the frequency of cells carrying transcriptionally active HIV-1 proviral DNA was reported to be at least 1 to 2 orders of magnitude lower than the total amount of infected cells (30) , indicating that the majority of infected cells exist in a state of transcrip-tional latency. The demonstration that defective HIV-1 particles can repress LTR-driven gene expression coupled with results indicating that the great majority of proviral DNA and circulating particles in HIV-1-infected individuals are defective (28, 47, 54, 64) suggests that noninfectious viruses may play a cardinal role in transcriptional latency. This may represent a strategy used by HIV-1 to favor virus transmission by preventing a rapid destruction of the host. Our data also suggest a novel mechanism by which defective particles could limit or interfere with replication of infectious viruses. Understanding of the mechanism of repression and of the cellular factor(s) involved in the present phenomenon may yield insights into the replicative cycle of HIV-1 and will permit the design of new therapeutic strategies that are less toxic and more efficient for the treatment of AIDS. Experiments are now in progress to identify cellular transducing elements involved in the signaling cascade which is initiated by the virus binding event.
